WASHINGTON, March 19, 2020 /PRNewswire/ -- Danaher
Corporation (NYSE: DHR) ("Danaher") announced today that the U.S.
Federal Trade Commission (the "FTC") has accepted the proposed
consent order in connection with Danaher's definitive agreement
with General Electric Company ("GE") (NYSE: GE) to acquire the
Biopharma business of GE Life Sciences ("GE Biopharma").
The acceptance by the FTC satisfies all required antitrust
clearances needed to be obtained for the acquisition of GE
Biopharma by Danaher. In addition to the FTC, the transaction has
also been cleared by the European Commission and the Brazilian,
Chinese, Israeli, Japanese, Korean and Russian antitrust
authorities. The closing of the acquisition remains subject to
other customary closing conditions set forth in the purchase
agreement. Danaher currently expects that the acquisition will be
completed on March 31, 2020.
ABOUT DANAHER
Danaher is a global science and
technology innovator committed to helping its customers solve
complex challenges and improving quality of life around the world.
Its family of world class brands has leadership positions in the
demanding and attractive health care, environmental and applied
end-markets. With more than 20 operating companies, Danaher's
globally diverse team of more than 60,000 associates is united by a
common culture and operating system, the Danaher Business System,
and its Shared Purpose, Helping Realize Life's Potential.
For more information, please visit www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release
that are not strictly historical, including the statements
regarding the anticipated acquisition of GE Biopharma and the
timing thereof and any other statements regarding events or
developments that we believe or anticipate will or may occur in the
future are "forward-looking" statements within the meaning of the
federal securities laws. There are a number of important factors
that could cause actual results, developments and business
decisions to differ materially from those suggested or indicated by
such forward-looking statements and you should not place undue
reliance on any such forward-looking statements. These factors
include, among other things, the parties' ability to satisfy the
remaining acquisition agreement conditions and consummate the
acquisition of GE Biopharma on the anticipated timetable and terms
or at all. Additional information regarding the factors that
may cause actual results to differ materially from these
forward-looking statements is available in our SEC filings,
including our 2019 Annual Report on Form 10-K. These
forward-looking statements speak only as of the date of this
release and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise.
View original
content:http://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html
SOURCE Danaher Corporation